12.21.2022 | CARB-X welcomes the G20 call to action on Antimicrobial resistance
Antimicrobial resistance (AMR) featured prominently on the G20 agenda during the past two months. In the G20 Bali Leaders’ Declaration, the G20 Heads of State and Government reiterated their commitment “to embedding a multisectoral One Health approach and enhancing global surveillance, including genomic surveillance, in order to detect pathogens and AMR that may threaten human health.” The G20 Health Ministers confirmed their support to “initiatives to catalyze AMR research and development” and published a detailed G20 Call to Action on Antimicrobial Resistance.
10.07.2022 | CARB-X convenes at ESCMID/ASM conference to lay the groundwork for the next decade
CARB-X is fully committed to addressing the global health threat of antimicrobial resistance. This week, its leaders convened at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance to lay the groundwork for CARB-X’s next decade, including plans to strengthen international collaboration and support, and to launch new funding rounds for product developers.
10.03.2022 | CARB-X launches new funding rounds for critical global health needs
CARB-X seeks preventatives, diagnostics and therapeutics that address neonatal sepsis, gonorrhea and the most threatening antimicrobial-resistant bacterial infections.
07.08.2022 | GARDP and CARB-X welcome renewed commitment by G7 leaders to address antimicrobial resistance
The Global Antibiotic Research and Development Partnership (GARDP) and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) jointly welcome the recent G7 Leaders’ Communiqué, which acknowledges the rapid rise in antimicrobial resistance (AMR) globally and renews the commitment by G7 governments to address the most dangerous drug-resistant infections.
06.16.2022 | CARB-X expands international reach with appointment of Damiano de Felice as Director of Development and External Engagement
CARB-X announced the appointment of Damiano de Felice, PhD, as Director of Development and External Engagement to the senior executive team. Dr. de Felice will manage CARB-X’s relationships with funders, investors in product developers and other organizations working to address antimicrobial resistance. He will also be responsible for the development of CARB-X’s financial sustainability strategy.
05.19.2022 | U.S. government and Wellcome commit up to an additional US$370 million to CARB-X
After celebrating its five-year anniversary in 2021, CARB-X (part of Boston University) announces renewed support from the U.S. Department of Health and Human Services (HHS) and Wellcome Trust, a U.K.-based global charitable foundation. The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within HHS, will provide US$20 million initially and up to US$300 million over 10 years to support the existing portfolio and launch new funding rounds. Wellcome will provide up to US$70 million over three years as part of its continued commitment to address the escalating threat of drug-resistant infections. Initial funding of $355 million from both BARDA and Wellcome originally launched CARB-X in 2016, and the new funding announced today builds on the success of this international non-profit partnership.